Clinical Trials

6,720 enrolled

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04633252 2026-05-27

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Phase 1/2 Recruiting

86 enrolled

Prostatic Neoplasms

NCT05675410 2026-05-27

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Phase 3 Recruiting

1,875 enrolled

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT06124157 2026-05-27

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 2 Recruiting

222 enrolled

Burkitt Lymphoma

NCT00092222 2026-05-22

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

75 enrolled

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT03223610 2026-05-22

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Phase 1/2 Recruiting

155 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

12 enrolled

Castrate Sensitive Prostate Cancer

NCT06317662 2026-05-22

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Phase 2 Recruiting

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT03269669 2026-05-13

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

73 enrolled

Phase 2/3 Active not recruiting

Lymphoma, Follicular

NCT03984448 2026-05-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

363 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

30 enrolled

Phase 2/3 Active not recruiting

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

422 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05896839 2026-05-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Phase 1/2 Recruiting

16 enrolled

Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT06649812 2026-05-13

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Phase 2 Recruiting

120 enrolled

Phase 1 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

16 enrolled

Ann Arbor Stage II Mantle Cell Lymphoma

NCT02883049 2026-05-04

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

5,949 enrolled 28 charts

Burkitt Lymphoma

NCT02003222 2026-05-01

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

488 enrolled 13 charts 1 FDA

Phase 1 Active not recruiting

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

12 enrolled 13 charts

Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

306 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT04739813 2026-04-29

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05389423 2026-04-28

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase 1 Recruiting

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT00792948 2026-04-13

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

97 enrolled 7 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02143414 2026-04-13

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

53 enrolled 12 charts

Phase 1 Active not recruiting

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03220022 2026-04-13

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

46 enrolled 19 charts

Lymphoma, AIDS-Related

NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

8 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Other hematologic neoplasm

10 enrolled 15 charts

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT00006436 2025-12-30

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

68 enrolled 24 charts

Acquired Immunodeficiency Syndrome, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related

NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

LymphoidMyeloidOther hematologic neoplasmPlasma cell

34 enrolled 18 charts

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Phase 1/2 Active not recruiting

17 enrolled 21 charts

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

348 enrolled 15 charts

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

NCT00001379 2025-06-19

Treatment and Natural History Study of Lymphomatoid Granulomatosis

94 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT00408005 2025-04-20

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Phase 3 Completed

1,895 enrolled 16 charts

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Phase 1 Completed

11 enrolled 16 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04933617 2024-07-09

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Phase 1 Terminated

8 enrolled 17 charts

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

107 enrolled 24 charts

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT01092182 2023-04-27

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

194 enrolled 19 charts

Plasmablastic Lymphoma, Burkitt Lymphoma, HIV Seropositivity, HIV Infections, Lymphoma, Large B-Cell, Diffuse

NCT00005780 2023-01-31

Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma

26 enrolled 18 charts

Lymphoma, Mantle-Cell

NCT01030900 2022-10-06

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

50 enrolled 13 charts

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00069238 2022-02-24

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

31 enrolled 12 charts

Lymphoma, Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell

NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Phase 1 Completed

15 enrolled 18 charts

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT00051311 2021-09-09

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

LymphoidOther hematologic neoplasmPlasma cell

62 enrolled 15 charts

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT01576172 2020-11-12

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

159 enrolled 12 charts

Prostatic Neoplasms

NCT00720109 2020-04-13

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2/3 Completed

63 enrolled 13 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Phase 1/2 Withdrawn

LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT01683994 2019-11-08

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

49 enrolled 18 charts

Prostatic Neoplasms

NCT01553188 2019-03-05

AMG 386 and Abiraterone for Advanced Prostate Cancer

36 enrolled 18 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Prostatic Neoplasms

NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Phase 2 Terminated

442 enrolled 17 charts

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT00942578 2018-10-11

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

63 enrolled 23 charts

Prostatic Neoplasms

NCT00436956 2018-10-09

AZD2171 to Treat Prostate Cancer

59 enrolled 12 charts

Prostatic Neoplasms

NCT00634647 2018-10-02

Satraplatin and Prednisone to Treat Prostate Cancer

24 enrolled 12 charts